CrossBridge Bio
Houston, US · Founded 2023 · United States corporation · 3 known investors
CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications. The company originated from ADC technology developed at the University of Texas Health Science Center at Houston.
Founders & leadership
CrossBridge Bio was founded in 2023 by Kyoji Tsuchikama and Michael Torres.
KT
Kyoji TsuchikamaCo-founder
MT
Michael TorresCo-founder
Board
WF
DI
Damir IllichBoard director
PJ
Patrick James CrutcherBoard director
Investors · 3
Funding
SEC filings, press & company announcements$10.8M disclosed across 1 of 2 rounds · 2024–2026
- Undisclosed amountSeed RoundApr 2026Source ↗
▶$10.8MraisedNov 2024 · 23 investors · BiotechnologyRule 506(b)
▶$10.8MraisedNov 2024 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William F. McKeonDirector
- Kyoji TsuchikamaExecutive Officer, Director, Promoter
- Damir IllichDirector
- Patrick James CrutcherDirector
- Michael TorresExecutive Officer, Director, Promoter
- Zhiqiang AnPromoter
- Offering amount
- $17M
- Amount sold
- $10.8M
- First sale
- Oct 2024
- Incorporated
- Corporation, United States, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Bridgebio5 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
ImmuneBridge5 shared keywordsImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
Fiveable3 shared keywordsFiveable provides AI-powered exam preparation for AP classes, offering practice questions with automated scoring and personalized study tools for high school students.
Companies competing with CrossBridge Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CrossBridge Bio do?
- CrossBridge Bio, launched in 2023, develops next-generation antibody-drug conjugates (ADCs) to address a range of cancer indications. The company originated from ADC technology developed at the University of Texas Health Science Center at Houston.
- Who founded CrossBridge Bio?
- CrossBridge Bio was founded by Kyoji Tsuchikama, Michael Torres in 2023.
- Who are CrossBridge Bio's investors?
- CrossBridge Bio's investors include Portal Innovations, TMC Venture Fund, Portal.
- How much funding has CrossBridge Bio raised?
- CrossBridge Bio has disclosed $10.8M raised across 1 of its 2 known rounds.
- Where is CrossBridge Bio headquartered?
- CrossBridge Bio is headquartered in Houston, US.